# Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission

> **NCT01018056** · PHASE4 · COMPLETED · sponsor: **Johns Hopkins University** · enrollment: 39 (actual)

## Conditions studied

- Tourette Syndrome

## Interventions

- **DRUG:** D-serine
- **DRUG:** Riluzole
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01018056
- **Lead sponsor:** Johns Hopkins University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2013-09
- **Final completion:** 2013-09
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2018-01-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01018056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01018056, "Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01018056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*